RenovoRx, Inc.(RNXT)

Biotechnology · Mountain View, CA

$1.39-0.08 (-5.44%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T21:08:18.522Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:08:18.522Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 62,623,253
Total debt · period ending 2026-06-30: 259,000
Cash · period ending 2026-06-30: 9,479,000
TTM operating EBITDA · period ending 2026-06-30: N/A

FMP input reference: f2bd7b982a7c38b7b5dde5784864fe9761ce9be9b841b4296251164aedb1f89c

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RNXT EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

RNXT Competitors' EV/EBITDA Ratio

RNXT

RenovoRx, Inc.

Current

Market Cap

$62.62M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs RNXT

Market Cap

$62.78M

EV/EBITDA Ratio

N/A

TTM Avg

250.18x

3Y Avg

250.18x

5Y Avg

250.18x

INCR

InterCure Ltd.

vs RNXT

Market Cap

$63.02M

EV/EBITDA Ratio

N/A

TTM Avg

7.83x

3Y Avg

18.88x

5Y Avg

17.80x

PLRX

Pliant Therapeutics, Inc.

vs RNXT

Market Cap

$63.78M

EV/EBITDA Ratio

N/A

TTM Avg

29.74x

3Y Avg

29.74x

5Y Avg

29.74x

ALPS

Alps Group Inc

vs RNXT

Market Cap

$64.18M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs RNXT

Market Cap

$60.42M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ONCY

Oncolytics Biotech Inc.

vs RNXT

Market Cap

$60.02M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XBIT

XBiotech Inc.

vs RNXT

Market Cap

$65.85M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CING

Cingulate Inc.

vs RNXT

Market Cap

$65.86M

EV/EBITDA Ratio

0.22x

TTM Avg

0.03x

3Y Avg

0.03x

5Y Avg

0.03x

GOSS

Gossamer Bio, Inc.

vs RNXT

Market Cap

$65.87M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
RenovoRx, Inc. (RNXT)	$62.62M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$62.78M	N/A	250.18x	250.18x	250.18x
InterCure Ltd. (INCR)vs ›	$63.02M	N/A	7.83x	18.88x	17.80x
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.78M	N/A	29.74x	29.74x	29.74x
Alps Group Inc (ALPS)vs ›	$64.18M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$60.42M	N/A	N/A	N/A	N/A
Oncolytics Biotech Inc. (ONCY)vs ›	$60.02M	N/A	N/A	N/A	N/A
XBiotech Inc. (XBIT)vs ›	$65.85M	N/A	N/A	N/A	N/A
Cingulate Inc. (CING)vs ›	$65.86M	0.22x	0.03x	0.03x	0.03x
Gossamer Bio, Inc. (GOSS)vs ›	$65.87M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics